Skip to content

Alto Neuroscience ANRO Interest Expense

Interest Expense at other companies

Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$8.06M+1.9%
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
$2.85M-6.4%
Alkermes logo
AlkermesALKS
$20.89M
Medtronic logo
MedtronicMDT
$176M+1.1%
Arrowhead Research logo
Arrowhead ResearchARWR
$23.85M+10.2%
IAR
Integra LifeSciencesIART
$22.47M+19.4%

Other financials

Income statement

See full
Operating income-$27.1M-73.1%
Net income-$26.2M-73.0%
EPS (diluted)-$0.80-42.9%

Balance sheet

See full
Cash & equivalents$264.3M+63.9%
Total debt$20.9M-17.2%
Total equity$243.4M+75.0%
Total assets$276.3M+60.7%

Cash flow

See full
Operating cash flow-$27.1M-63.6%
CapEx$556.0K+2,217%
Free cash flow-$27.6M-66.7%

Valuation

See full
Market cap$887.88M+1,358%
Enterprise value$644.49M-958%

Returns & leverage

See full
Return on equity-38.9%+0.9pp
Debt / equity0.1×-0.1×
Current ratio20.5×-2.0×

Where this comes from

Reported directly by Alto Neuroscience in its filing.

Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.

The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alto Neuroscience's interest expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alto Neuroscience's interest expense?
Alto Neuroscience (ANRO) reported interest expense of $545K in Q1 2026.
How has Alto Neuroscience's interest expense changed year-over-year?
Alto Neuroscience's interest expense decreased by 8.9% year-over-year, from $598K to $545K.
What is the long-term trend for Alto Neuroscience's interest expense?
Over 2 years (2023 to 2025), Alto Neuroscience's interest expense has grown at a 34.2% compound annual growth rate (CAGR), from $1.37M to $2.47M.
What does interest expense mean?
Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.